Progyny (PGNY) Stock Looks Undervalued Broadly But Fairly Valued On Earnings

Progyny stock has delivered mixed results for long term holders, with the share price down about 55.0% over the past 5 years even as shorter term returns have been more resilient. At the same time, the broader valuation checks currently lean cheap, which raises questions about how to weigh that longer share price decline against what the current multiples suggest.

• The roughly 55.0% decline over 5 years signals that long term Progyny investors have absorbed a significant drawdown that still colors how the market prices the stock today.
• Progyny’s ability to grow revenue efficiently while managing the costs and underwriting risks of fertility benefits contracts can support or undermine what investors are willing to pay for each dollar of business the company writes.
• On the broad valuation screen, Progyny looks inexpensive on most checks, with a high value score of 5, which suggests the stock leans cheap rather than richly priced.

For investors, the debate is whether the current share price already reflects the long term risks around Progyny’s business model, or whether the high value score signals room for the stock to better reflect its fundamentals.

Compare Progyny’s setup with hand picked value opportunities by scanning the 45 high quality undervalued stocks that share strong business fundamentals and currently appear inexpensive on key valuation checks.

Does Progyny Look Fairly Valued on Earnings?

The P/E ratio is a useful way to look at Progyny because the company currently reports positive earnings. Progyny trades on a P/E of about 25.4x, which is close to the Healthcare industry average of roughly 25.0x and below the estimated peer average of about 39.1x.

The tailored fair P/E ratio for Progyny is calculated at around 27.4x, which takes into account its sector, profitability profile, size and risk. That is only a small premium to where the stock trades today. On this framework, Progyny stock does not screen as especially cheap or especially expensive on earnings, but rather in line with what the model suggests is reasonable.

On the P/E multiple, Progyny looks roughly fairly valued, with its earnings rating and market price sitting close to the modelled fair level.

See what the numbers say about this price — find out in our valuation breakdown.

The Progyny Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Progyny pick up where the valuation checks stop. They spell out the specific paths for Progyny's revenue, margins and earnings that would need to play out for the stock to be worth materially more or materially less than today’s price. They are available on the company’s Community page so you can see how those assumptions evolve over time. Where a single ratio or model gives one headline figure, these break down the future it relies on so you can monitor whether that story still holds.

One of the top community narratives on Progyny: 13% undervalued

"As efforts to curb healthcare costs intensify in the U.S., future policy actions could restrict employer funding or insurance coverage for fertility benefits, which could severely limit Progyny's customer base and stall revenue growth."

Read one of the top narratives on Progyny

Do you think there's more to the story for Progyny? Head over to our Community to see what others are saying!

The Bottom Line

Progyny now looks roughly in line with what its tailored P/E suggests, so the stock is not clearly undervalued or overvalued on earnings alone. Broader valuation checks lean supportive, which makes the key question whether the current multiple already reflects the policy and customer concentration risks that come with fertility benefits. For you as an investor, the crux is simple. The outcome hinges on whether Progyny can keep converting its benefits model into resilient revenue and margin performance that justifies holding a market level multiple over time.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com